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To describe prevalence and impact of peripheral arterial disease (PAD) in patients with acute coronary syndrome (ACS), data were
collectedover5monthsfrom6MiddleEasterncountries.Patientsweredividedinto2groups(withandwithoutPAD).Outof6705
consecutive ACS patients, PAD was reported in 177 patients. In comparison to non-PAD, PAD patients were older and more likely
to have cardiovascular risk factors. They were more likely to have high Killip class, high GRACE risk score, and non-ST elevation
ACS (NSTEACS) at presentation. Thrombolytics, antiplatelet use, and coronary intervention were comparable in both groups.
When presented with ST-elevation myocardial infarction (STEMI), patients with PAD had worse outcomes, while in NSTEACS;
PAD was associated with higher rate of heart failure in comparison to non-PAD patients. In diabetics, PAD was associated with
2-fold increase in mortality when compared to non-PAD (P = 0.028). After adjustment, PAD was associated with high mortality
in STEMI (adjusted OR 2.6; 95% CI 1.23–5.65, P = 0.01). Prevalence of PAD in ACS in the Gulf region is low. Patients with PAD
and ACS constitute a high risk group and require more attention. PAD in patients with STEMI is an independent predictor of
in-hospital death.
1.Introduction
The prevalence of peripheral arterial disease (PAD) is
variable and relatively high in the western world [1–4].
Patients with PAD are at increased risk of coronary, carotid
and cerebrovascular atherosclerosis disease, and all-cause
mortality [5–8]. This risk is independent of the traditional
riskfactorssuchasdiabetesmellitus, hypertension,smoking,
and obesity [8–10]. PAD is not a static disease and its
progression from intermittent claudication to rest pain or
gangrene can occur [7–10]. It is possible that the functional
impairment in patients with PAD may keep them from
ambulating to the point of having angina to the extent
that those patients may present with much more advanced
coronary atherosclerosis [5]. This risk becomes greater as
the severity of PAD increases [7, 8]. Several studies have
shown worse prognosis in acute coronary syndrome (ACS)
when PAD present in both selected and unselected western
population admitted with ACS [1, 3, 5, 11–15]. However,
the prevalence and the impact of PAD in patients with2 International Journal of Vascular Medicine
acute coronary syndrome in the Middle Eastern countries
are limited. The aim of the current study is to study the
prevalence of the PAD and to evaluate its impact on the in-
hospital mortality and major adverse cardiac events across
the ACS population in the Middle Eastern population.
2. Methods
For the purpose of the current analysis, data for 6705
consecutive ACS patients was collected from a 6-month
prospective, multicenter study of the Gulf Registry of Acute
Coronary Events (Gulf RACE) from 6 adjacent Middle East-
ern Gulf countries (Bahrain, Kuwait, Qatar, Oman, United
Arab Emirates, and Yemen). Patients were recruited from
64 hospitals with the diagnosis of ACS including unstable
angina (UA) and non-ST- and ST-elevation myocardial
infarction (NSTEMI and STEMI). There were no exclusion
criteria and thus all the prospective patients with ACS
were actually enrolled. The study received ethical approval
from the institutional ethical bodies in all participating
countries. Full details of the methods have been published
[16, 17]. Data were collected on record forms by the
treating physicians. Completed data sheets were sent to the
central data processing center, for uniform monitoring and
registration. We analyzed patients with peripheral arterial
disease (PAD) compared them with those who did not have
PAD.
2.1. Deﬁnitions. Brieﬂy, diagnosis of the diﬀerent types
of ACS and deﬁnitions of data variables were based on
the American College of Cardiology clinical data standard
[18]. For the purpose of this report, ST-segment elevation
myocardial infarction and left bundle branch block myocar-
dial infarction were grouped together and called STEMI,
whereas merging NSTEMI and unstable angina patients
called NSTEACS.
2.2. Peripheral Arterial Disease. In addition to well-
documented previous history of PAD (i.e., vascular surgery
or angioplasty), ankle-brachial index (ABI) of <0.8 in
either leg was used as cut point for the presence of PAD. To
calculate the ABI ratio, the average systolic blood pressure
measurement in the ankle was divided by the average systolic
blood pressure measurement in the arm. The mean pressure
of the higher arm was used to calculate the ABI separately
for each leg.
2.3. Statistical Analysis. Patients were divided into 2 groups
(with and without PAD). Clinical and biochemical variables,
comorbidities and in-hospital medical treatment in ACS
patients were analyzed in both groups. Data were presented
as proportion or mean ± standard deviation (SD) as appro-
priate. Diﬀerencesin categoricalvariablesbetweenrespective
comparison groups were analyzed using the χ2 test. The con-
tinuous variables were analyzed using independent-samples
t-test. The primary end points were analyzed and compared
in the diﬀerent groups using the χ2 test. Multivariate logistic
regression analysis was carried out after controlling for the
relevant variables for the predictors of hospital outcomes.
Primary end points included in-hospital reischemia, heart
failure (HF), and mortality. The multivariate analysis was
adjusted for following potential covariates: age, sex, dia-
betes mellitus, hypertension, aspirin, heparin, glycoprotein
inhibitors, and coronary angiography. Adjusted odds ratios,
with accompanying 95% conﬁdence intervals, were reported
for the respective categories. Moreover, multivariate logistic
regression analysis was carried out after controlling for the
relevant variables for the predictors of PAD. All P values
were two-sided tailed. P values of <0.05 were considered
signiﬁcant. All data analyses were carried out using the
Statistical Package for Social Sciences version 18 (SPSS Inc.
USA). For the purpose of comparing our ﬁndings with
the western experiences, we selected 4 western originated
studies that were conducted on PAD patients presenting with
ACS. These studies were SPRINT (Secondary Prevention
Study Reinfarction Israeli Nifedipine Trial), GRACE (Global
Registry of Acute Coronary Events), PAMISCA (Prevalencia
de Afectaci´ on de Miembros Inferiores en el paciente con
S´ ındrome Coronario Agudo), and MASCARA (Manejo del
SindromeCoronarioAgudo.RegistroActualizado)[1,11,14,
15].
3. Results
3.1. Clinical and Biochemical Proﬁles. Out of the 6705
patientswhowereadmittedwithACS,PADwasdocumented
in 177 patients (2.6%). Table 1 shows the baseline character-
istics and risk factors of patients with PAD in comparison
to non-PAD patients. Patients with PAD were 9 years older
(65 ± 11 versus 56 ± 12, P<0.0001), and were more likely
to be female (35% versus 24%, P<0.001). PAD patients
were also more likely to have diabetes mellitus (69% versus
40%, P<0.001), hypertension (77% versus 50%, P<0.001),
dyslipidemia (66% versus 31%, P = 0.001), previous history
of CAD (79% versus 45%, P<0.001), prior coronary
revascularization (35% versus 15%, P<0.001), chronic lung
disease (17.5% versus 5%) and renal failure (45% versus
17%, P = 0.001). They were less likely to be smokers (32%
versus 38%, P = 0.001). At presentation with ACS, PAD
patients had higher heart rate, Killip class, and GRACE risk
score (P<0.001 for all). Mean total cholesterol was lesser in
PAD group (4.6 ±1.5versus5.02 ±2.3,P = 0.001)andmean
serum triglyceride value was comparable in the 2 groups.
NSTEACS was the most frequent diagnosis in PAD patients,
whereas STEMI was the predominant diagnosis in non-PAD
group.
3.2. In-Hospital Treatment Pattern. Table 2 demonstrates the
treatment patterns for patients with and without PAD. In
regard to on admission therapy, there were no diﬀerences
between the two groups in the use of oral and intravenous
antiplatelet medications, thrombolysis therapy, angiotensin-
converting enzyme, or angiotensinogen-receptor inhibitors
use. Coronary interventions were also comparable in the 2
groups.InPADgroup,unfractionatedheparinandβ-blocker
were used less frequently (P = 0.001), while low molecularInternational Journal of Vascular Medicine 3
Table 1: Clinical and biochemical proﬁles of patients with acute coronary syndrome.
Non-PAD (N = 6528) PAD (N = 177) P value
Age (mean) 56 ± 12 65 ± 11 0.001
Females (%) 1571 (24) 61 (35) <.001
Prior coronary artery disease (%) 2929 (45) 140 (79) <.001
Prior coronary revascularization (%) 987 (15) 62 (35) <.001
Family history of CAD (%) 873 (13) 29 (16) 0.87
Diabetes mellitus (%) 2622 (40) 123 (70) <.001
Hypertension 3228 (50) 136 (77) <.001
Smoking (%) 2491 (38) 56 (32) <.001
Dyslipidemia (%) 2034 (31) 116 (66) <.001
Prior aspirin use (%) 2644 (41) 141 (80) <.001
Renal failure (%) 1091 (17) 80 (45) <.001
Chronic lung disease (%) 335 (5) 31 (17.5) <.001
Heart rate (mean, b/min) 86 ± 22 93 ± 27 <.001
SBP (mean, mmgh) 140 ± 30 137 ± 33 0.26
DBP (mean, mmgh) 84 ± 17 78 ± 18 0.001
BMI (mean) 27.6 ± 5 27.4 ± 50 . 7 7
Ischemic chest pain, n (%) 5223 (80) 121 (68) <.001
Late presentation 801 (31) 13 (28) 0.61
Killip class >I, n (%) 1392 (21) 79 (45) <.001
LV ejection fraction <40% (%) 890 (22) 40 (33) 0.007
NSTEACS 3957 (61) 129 (73) 0.001
STEMI/LBBB 2571(39) 48 (27) 0.001
GRACE risk Scoring
Low, n (%) 2047 (43) 14 (11)
<.001 Medium, n (%) 1341 (28) 22 (18)
High, n (%) 1390 (29) 90 (71)
Biochemical ﬁndings
First blood sugar (mg/dL) 11 ± 10 13 ± 7 <.001
Fasting blood sugar (mg/dL) 8 ± 89 ± 40 . 0 2
Peak troponin (ng/mL) 17 ± 51 7 ±30 0.04
First creatinine (μmol/L) 107 ± 92 163 ±139 <.001
Total cholesterol 5 ± 24 . 6 ± 1.5 <.001
HDL(μmol/L) 1.03 ± 1.2 0.97 ± 0.7 0.22
LDL(μmol/L) 3.3 ± 34 . 6 ± 2 0.001
Fasting triglyceride (μmol/L) 1.9 ± 21 . 8 ± 1.2 0.77
First haemoglobin (mean, gm/L) 14 ± 41 3 ± 6 0.009
PCI: Percutaneous coronary interventions, CAD: coronary artery disease, SBP: systolic blood pressure, DBP: diastolic blood pressure. GRACE: Global registry
of acute coronary events.
weight heparin was more frequently used (P = 0.03). At
discharge, aspirin and β-blocker were less likely used (P =
0.001), while clopidogrel and statin were more likely used in
PAD group (P = 0.03 and 0.01 resp.).
3.3. In-Hospital Clinical Outcomes. Table 3 shows hospital
outcomes in overall, STEMI and NSTEACS patients. In
overall ACS and STEMI, all the primary end points were
signiﬁcantly worse in PAD group in addition to the higher
percent of bleedings and stroke. In NSTEACS patients, there
were no signiﬁcant diﬀerences between the groups except for
the high percent of the incidence of heart failure in PAD
group (24% versus 16%, P = 0.009). Hospital stay was
signiﬁcantly prolonged in PAD group in overall (6.2 versus
5.6 days, P = 0.03) and NSTEACS (6.4 versus 5.2 days,
P = 0.003) patients. In diabetic patients, PAD was associated
with 2-fold increase in mortality when compared to non-
PAD (8% versus 4%, P = 0.028) (Figure 1). There was a
signiﬁcant main eﬀect for PAD (P = 0.008) and not for
DM (P = 0.63) on the mortality; there was no interaction
between the two variables (P interaction = 0.98).
3.3.1. Multivariate Logistic Regression Analysis (Figure 2).
After adjustment for the important variables (traditional
risk factors), the independent predictors for PAD were
DM (OR1.9; 95% CI 1.36–2.77), renal failure (OR 2.5;4 International Journal of Vascular Medicine
Table 2: Management of patients with acute coronary syndrome.
No-PAD PAD P value
On admission medications
Thrombolysis, n (%) 1494 (58) 24 (51) 0.34
Aspirin, n (%) 6391(98) 172 (97) 0.49
Clopidogrel, n (%) 3499 (54) 106 (60) 0.09
Heparin, n (%) 3093 (48) 67 (38) 0.01
LMW Heparin, n (%) 3073 (47) 98 (55) 0.03
Gp IIb/IIIa inhibitor, n (%) 677 (10) 23 (13) 0.26
β-Blocker, n (%) 4277 (66) 84 (48) 0.001
ACE/ARB, n (%) 4498 (69) 120 (68) 0.74
Coronary angiography (%) 1217 (19) 33 (19) 0.99
PCI, n (%) 273 (19.14.2) 7 (19.94) 0.88
Discharge medications
Aspirin, n (%) 6155 (95) 150 (85) 0.001
Clopidogrel, n (%) 3204 (49) 101 (57) 0.03
Statin, n (%) 5264 (81) 156 (88) 0.01
ACE/ARB, n (%) 4950 (76) 132 (75) 0.66
β-Blocker, n (%) 4939 (76) 107 (61) 0.001
Diuretics, n (%) 4561(70) 134 (76) 0.11
Table 3: Clinical outcomes in patients with acute coronary
syndromes.
Non-PAD PAD P value
Overall
In-hospital death, n (%) 233 (4) 14 (8) 0.002
Heart failure, n (%) 1044 (16) 55 (31) 0.001
Recurrent ischemia, n (%) 580 (10) 24 (14) 0.03
Re-infarction, n (%) 151 (2.3) 2 (1.1) 0.29
Major bleeding, n (%) 46 (0.7) 6 (3.4) 0.001
Stroke, n (%) 45 (0.7) 4 (2.3) 0.01
Hospital stay (mean) (days) 5.6 ± 4.6 6.2 ± 4.2 0.03
STEMI/LBBB
In-hospital death, n (%) 161 (6) 11 (23) 0.001
Heart failure, n (%) 430 (17) 24 (50) 0.001
Recurrent ischemia, n (%) 233 (9) 9 (19) .02
Major bleeding, n (%) 26 (1) 5 (10) 0.001
Stroke, n (%) 29 (1.1) 3 (6.4) 0.001
Hospital stay (mean) (days) 6.14 ± 4.3 5.8 ± 3.7 0.58
NSTEACS
In-hospital death, n (%) 72 (1.8) 3 (2.3) 0.67
Heart failure, n (%) 614 (16) 31 (24) 0.009
Recurrent ischemia, n (%) 347 (9) 15 (12) 0.27
Major bleeding, n (%) 20 (0.5) 1 (0.8) 0.67
Stroke, n (%) 16 (0.4) 1 (0.8) 0.52
Hospital stay (mean) (days) 5.17 ± 4.8 6.4 ± 4.4 0.003
95% CI 11.79-3.43), smoking (OR 1.8; 95% CI 1.23–2.63),
prior CAD (OR 2.3; 95% CI 1.49–3.38), and dyslipidemia
(OR 2.3; 95% CI 1.54–3.22). For in-hospital mortality,
after adjusting for relevant variables including age, sex,
risk factors, treatment, and coronary angiography, PAD was
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Figure 1: Mortality rate in peripheral arterial disease (PAD)
patients presenting with acute coronary syndrome patients and
stratiﬁed by the diabetic status (DM).
an independent predictor of mortality in STEMI patients
(adjusted OR 2.6; 95% CI 1.23–5.65, P = 0.01).
4. Discussion
The current study demonstrated the prevalence and impact
of PAD among patients presenting with ACS who are
living in the Middle East. There are several key ﬁndings
in the present study. Firstly, the prevalence of PAD among
ACS patients is low in the gulf region in comparison to
the western populations [1, 3, 11–15]. This ﬁnding may
indicate the underestimation or missed PAD diagnosis in
the initial evaluation of ACS patients. Secondly, PAD is
a marker of worse baseline cardiovascular risk proﬁle. In
overall ACS and STEMI, patients with PAD developed worse
in-hospital outcomes in terms of greater rate of death,
heart failure, recurrent ischemia, stroke, and major bleeding
when compared to their non-PAD counterparts. This was
consistent with the previous western studies [1, 11, 14, 15].
Even after adjusting for the potential relevant covariants,
PAD was an independent predictor for mortality in STEMI
patients in the current study. PAD increased the rate of
death almost 3 times in comparison to non-PAD patients.
In NSTEACS patients, PAD was associated with signiﬁcant
higher rate of heart failure in comparison to non-PAD. ThisInternational Journal of Vascular Medicine 5
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Figure 2: (a) predictors for peripheral arterial disease, (b) clinical predictors for in-hospital mortality in ST-elevation myocardial infarction.
was consistent with the data from the CRUSADE registry in
which PAD was an independent predictor of HF in NSTACS
patients [5]. Thirdly, in diabetic patients, PAD increased
in-hospital mortality rate twice when compared to their
counterpart non-PAD patients. In a recent study, Laﬁtte
et al. [19] reported 3-fold increase in the risk of cardiovascu-
lar (CV) events in patients with both PAD and diabetes even
after optimization of risk-factor control and medications.
This long-term high CV risk was not signiﬁcant in diabetic
patients without PAD.
Previous studies reported that although PAD patients
were high risk group, they were less likely to be appropriately
treated with evidence-based therapy and this may in part
explain the worse outcomes [3, 4, 12, 13]. However, in the
current study, there were no signiﬁcant diﬀerences in the
management between the 2 groups apart from the fewer use
of β blockers in PAD group. β blockers were not frequently
used because of the presence of PAD per se and high
percent of chronic lung disease in the PAD group. Fourthly,
PAD patients ranked high GRACE risk scoring in patients
presentingwithACS;thismightbeusefulsimplebedsidetool
for early risk-stratiﬁcation of those patients.
Many traditional and emergent CV risk factors are more
prevalent in patients with ACS and PAD. Also, certain factors
are independent predictors of PAD [10]. However, the asso-
ciated increased CV risk is independent of those traditional
risk factors. The main independent predictors for PAD in the
present study included DM, renal failure, prior CAD, and
dyslipidemia. The prevalence of PAD in patients with ACS
has been reported in several studies in the range of 1% to
39.8% [20–22]. This wide range is inﬂuenced by the same
factors as the patients without ACS. The prevalence of PAD
among patients with CAD varies between studies according
to the method of diagnosis [2]. The PAD prevalence ranged
between 2.4 in the current study to 39.8 in the PAMISCA
study (Table 4). The prevalence in the PAMISCA study was
higher than all the other studies and the authors attributed
this to the high subclinical PAD patients and the exclusion6 International Journal of Vascular Medicine
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of patients younger than 40 years of age. In our study, the
presence of PAD is probably underestimated in part due to
the inclusion criteria (ABI of <0.8), the high prevalence of
diabetes mellitus (70%) which can lead to a false elevation
of the ankle pressure, and slightly younger age group. The
present study reported the highest prevalence of diabetes
mellitus when compared to other studies which ranged from
25% to 49.4%. Hypertension and dyslipidemia were higher
inpatientswithPADwhencomparedwithnon-PADpatients
in all the studies. On the other hand, smoking was lower in
patient with PAD compared to non-PAD patients in all the
studieswiththeexceptionofGRACEstudy.Therewerefewer
smokers in PAD group in the present study, but interestingly,
in multivariate logistic regression analysis, smoking became
one of the independent predictors for PAD. Recently, Conen
et al. [23] assessed the association of smoking status with
PAD in healthy women. The investigators reported that
smoking was a potent risk factor for symptomatic PAD
and was associated with subclinical inﬂammation. Also, they
observed that smoking cessation substantially reduced risk
for PAD, but an increased occurrence of PAD persisted even
among former smokers [23].
Data on the prevalence and outcome of Middle Eastern
patients with PAD are very limited. Al Zahrani et al. [24]i n
across-sectionalhospital-basedstudy(402patients)inSaudi
ArabiareportedhighprevalenceofPAD(ABI<0.9)inelderly
high risk patients with either diabetes mellitus (61.4%),
chronic renal failure (13.4%), or ischemic heart disease
(21.4%) when compared to controls (4.1%). Previously, we
conducted a cross-sectional multicenter study in 5 Middle
Eastern countries [25]. The study enrolled 1,341 patients
who were either (1) with cardiovascular disease (cerebrovas-
cular, ischemic heart disease, and/or peripheral vascular
disease) or (2) were at risk of developing cardiovascular
disease based on the presence of cardiovascular risk factors.
At that study, we reported high prevalence of PAD based
on ABI <0.9 (31.5% and 28.2%, resp.). The current study
extended these observations and reported for the ﬁrst time,
in our region, the prognostic impact of PAD among ACS
patients.
Our data were collected from an observational study
which is one of the limitations. However, well-designed
observational studies provide valid results and do not
systematically overestimate the results compared with the
results of randomized controlled trials. Moreover, inconsis-
tent cutoﬀ points for ABI would potentially miss patients
with milder PAD leading to potential outcome bias in
diﬀerent studies.
5. Conclusion
Prevalence of PAD in ACS in the Gulf region is low.
Patients with PAD and ACS are high risk group that
require more attention for risk factors and early detection.
Certain traditional risk factors are independent predictors
for PAD necessitates aggressive preventive measures. PAD
in patients with STEMI is an independent predictor for in-
hospital death. Detection of PAD in ACS patients might be
a useful simple bedside tool for early detection of the risk
stratiﬁcation.
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